HopeStage
Back to all studies
CompletedNCT05790252

Buprenorphine patch induction during pregnancy: BRIDGE study

About this titleRead the official source — NCT05790252
Medication studyAges 18–110United StatesAddiction
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 110 years.

Listed locations
St LouisSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: November 27, 2023
Recruitment status
Completed
Enrollment listed in the registry
7
Sponsor
Washington University School of Medicine
Sponsor type
University
Study type
Drug
Intervention type
Drug, Other
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 18 Years to 110 Years
Official registry ID
NCT05790252
Official title
Show the full official title

Using the Transdermal Patch for BupRenorphine Induction DurinG PrEgnancy: A Randomized Controlled Trial (The Patch BRIDGE Trial)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

St Louis

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Washington University School of Medicine, a university.

Did this study involve medication?

Yes. The study involved medication, including Buprenorphine Transdermal Matrix Patch.

Who was this study for?

Listed age limits: 18 years to 110 years.

Want to explore more studies?

Explore studies